Drug intelligence / Profile preview

inetetamab + rapamycin + chemotherapy

Development stage: Unknown
Lead developer: Peking Union Medical College
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This combination therapy regimen consists of inetetamab, rapamycin (sirolimus), and chemotherapy. Inetetamab is an innovative, Fc-engineered recombinant anti-HER2 humanized monoclonal antibody designed to enhance antibody-dependent cellular cytotoxicity (ADCC) compared to standard trastuzumab. Rapamycin is a small molecule inhibitor of the mammalian target of rapamycin (mTOR), which targets the PI3K/Akt/mTOR signaling pathway often implicated in resistance to HER2-targeted therapies. The regimen is currently being evaluated in a Phase 3 clinical trial (NCT04736589) sponsored by Peking Union Medical College for patients with HER2-positive metastatic breast cancer who have progressed on trastuzumab and possess mutations or abnormal activation in the PI3K/Akt/mTOR pathway.

Brand names: Cipterbin
Other names: Inetetamab plus Rapamycin plus chemotherapyCipterbin + sirolimus + chemotherapy

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on inetetamab + rapamycin + chemotherapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on inetetamab + rapamycin + chemotherapy.

Explore the full profile